Lexpos News

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 16 Issue 9 April 2023) has been published and includes articles on: Isotretinoin (Roaccutane▼): new safety measures to be introduced in the coming months. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular eventss, malignancy, venous thromboembolism, serious infections [...]

The post MHRA Drug Safety Update April 2023 appeared first on PSNC Website.

Class 4 Medicines Defect Information: Beconase Hayfever Nasal Spray (Omega Pharma Ltd) Drug alert number: EL (23)A/15 Date issued: 26 April 2023 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Product name:Beconase Hayfever Nasal Spray, PL 02855/0064 (Omega Pharma Ltd) SNOMED Code:2945411000001101 Batch No Expiry [...]

The post Class 4 Medicines Defect Information: Beconase Hayfever Nasal Spray (Omega Pharma Ltd) appeared first on PSNC Website.

In today’s session of Prime Minister’s questions, Sir George Howarth MP dedicated his question to the issue of pharmacy closures and the need for Government to do more to support the sector, including commissioning a fully funded Pharmacy First service. Sir George is a strong supporter of community pharmacies and has attended several recent pharmacy-focussed [...]

The post MP raises pharmacy closures during Prime Minister’s Questions appeared first on PSNC Website.

The Department of Health and Social Care (DHSC) has today (25/04/2023) granted the following list of price concessions for April 2023: Drug Pack size Price concession Buprenorphine 8mg sublingual tablets sugar free 7 £4.41 Calcipotriol 0.005% / Betamethasone dipropionate 0.05% ointment 30 £9.23 Carbocisteine 375mg capsules 120 £7.24 Chloramphenicol 1% eye ointment 4 £5.20 Chlorpromazine [...]

The post April 2023 Price Concessions 3rd Update appeared first on PSNC Website.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxybutynin 5mg modified-release tablets. MSN/2023/048 Tier 2 – medium impact Date of issue 24th April 2023 Oxybutynin 5mg modified-release tablets are out of stock until w/c 1st May 2023. Oxybutynin immediate release formulations (tablets and liquid) remain available and can support [...]

The post Medicine Supply Notification: Oxybutynin 5mg modified-release tablets appeared first on PSNC Website.